tbuckley/cabot-search huggingface dataset:
Extracellular Nicotinamide Phosphoribosyltransferase (NAMPT) Shapes the CLL Microenvironment Promoting Macrophage M2 Polarization Via a Non-Enzymatic Mechanism
Authors: Valentina Audrito, Sara Serra, Davide Brusa, Francesca Mazzola, Francesca Arruga, Tiziana Vaisitti, Marta Coscia, Rossana Maffei, Davide Rossi, Tao Wang, Giorgio Inghirami, Menico Rizzi, Gianluca Gaidano, Cynthia Wolberger, Nadia Raffaelli, Silvia Deaglio
Journal: Blood (2014)
Infusion of Ex Vivo Expanded Allogeneic Cord Blood-Derived Natural Killer Cells in Combination with Autologous Stem Cell Transplantation for Multiple Myeloma: Results of a Phase I Study
Authors: Nina Shah, Li Li, Indreshpal Kaur, Jessica McCarty, Eric Yvon, Hila Shaim, Muharrem Muftuoglu, Enli Liu, Catherine Sobieski, Robert Z. Orlowski, Laurence J.N. Cooper, Dean A. Lee, Simrit Parmar, Kai Cao, Chitra M. Hosing, Sairah Ahmed, Yago Nieto, Qaiser Bashir, Krina K Patel, Catherine M. Bollard, Ian K. McNiece, Muzaffar Qazilbash, Richard E. Champlin, Katayoun Rezvani, Elizabeth J. Shpall
Journal: Blood (2015)
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Harbors Frequent Splicesosome Mutations That Cause Aberrant RNA Splicing Affecting Genes Critical in pDC Differentiation and Function
Authors: Katsuhiro Togami, Vikas Madan, Jia Li, Alexandra-Chloe Villani, Siranush Sarkizova, Mahmoud Ghandi, Kevin Buczkowski, Yvonne Li, Sabeha Biichle, Fanny Angelot-Delettre, Michael Seiler, Silvia Buonamici, Justin Taylor, Omar Abdel-Wahab, Peter S Hammerman, Nir Hacohen, Henry Yang, Francine Garnache-Ottou, H. Phillip Koeffler, Andrew A. Lane
Journal: Blood (2016)
Isolation, Phenotypic, Molecular and First-Time Proteomic Characterization of Human Mesenchymal Stem Cells (MSCs) Derived from Amniotic Fluid: Comparison to Bone Marrow MSCs.
Authors: Maria G. Roubelakis, Kalliopi I. Pappa, Vassiliki Bitsika, Dimitra Zagoura, Antonia Vlahou, Helen Papadaki, Aristidis Antsaklis, Nicholas P. Anagnou
Journal: Blood (2006)
Low grade glioma patients: how does this patient group perceive their quality of life prior to surgical or oncological interventions?
Authors: Charlotte Robinson, Jose Pedro Lavrador, Richard Gullan, Lucy Brazil, Angela Swampillai, Omar Al’Salihi, Ranj Bhangoo, Francesco Vergani, Vicky Hurwitz, Jess La, Laura Mullens, Liz Ford, Maria Mcewan, Keyoumars Ashkan
Journal: Neuro-Oncology (2019)

Abstract Introduction Literature analysing how patients with a provisional low-grade glioma perceive their own quality of life prior to any surgical or oncological intervention is scarce. This patient group are often highly functioning individuals, able to lead ordinary lives which stresses that their management must be carefully considered in a holistic sense. Low grade gliomas represent 5 % of brain tumours and they are typically of a younger cohort who will be less equipped to manage the uncertainties a diagnosis like this brings. Methods Prospective single centre cohort study over 14 months where 56 patients completed the EORTC QLQ – BN 20 and 30 prior to initial consultation in the dedicated low grade glioma clinic. Results 54% of patients did not feel ‘limited in doing work or other daily activities’ but of those who were affected to some degree, 21% of women felt ‘very much affected’ compared to 3% of men. 78% of patients expressed to a degree some ‘uncertainty about the future’ and this was shown to be a common theme among all age groups which reflects the huge burden of anxiety this patient group faces regardless of age. Conclusion Data demonstrated a variety of quality of life scores that are not particular to a certain age group/gender which reinforces the importance of individual assessment as assumptions of patients in a particular category cannot be made. By assessing quality of life, clinical management is improved as a more in-depth assessment is facilitated on an individual basis and patient experience is enhanced.
Randomized Phase 2 Study of the All-Oral Combination of Investigational Proteasome Inhibitor (PI) Ixazomib Plus Cyclophosphamide and Low-Dose Dexamethasone (ICd) in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Who Are Transplant-Ineligible (NCT02046070)
Authors: Meletios A. Dimopoulos, Sebastian Grosicki, Wieslaw W Jedrzejczak, Hareth Nahi, Astrid Gruber, Markus Hansson, Catriona Byrne, Richard Labotka, Ai-Min Hui, Zhaoyang Teng, Norbert Grzasko
Journal: Blood (2015)
Hematopoietic Stem Cell Transplantation (HSCT) after a Myeloablative Conditioning Regimen in Children with Refractory Cytopenia (RC): Results of a Retrospective Analysis from the EWOG-MDS Group.
Authors: Franco Locatelli, Peter Noellke, Alexandra Fisher, Peter Bader, Maria Ester Bernardo, Eva Bergstraesser, Henrik Hasle, Marry van den Heuvel-Eibrink, Elisabeth Korthof, Jan Stary, Brigitte Strahm, Felix Zintl, Petr Sedlacek, Marco Zecca, Charlotte M. Niemeyer
Journal: Blood (2007)
Down-regulated RGS5 by genetic variants impairs endothelial cell function and contributes to coronary artery disease
Authors: Yang Li, Han Yan, Jian Guo, Yingchun Han, Cuifang Zhang, Xiuying Liu, Jie Du, Xiao-Li Tian
Journal: Cardiovascular Research (2019)

Genetic contribution to coronary artery disease (CAD) remains largely unillustrated. Although transcriptomic profiles have identified dozens of genes that are differentially expressed in normal and atherosclerotic vessels, whether those genes are genetically associated with CAD remains to be determined. Here, we combined genetic association studies, transcriptome profiles and in vitro and in vivo functional experiments to identify novel susceptibility genes for CAD.
Leukocyte Apoptosis and Mitochondrial Dysfunction in β-Thalassemia Patients Treated with Deferasirox or Deferoxamine.
Authors: Patrick B. Walter, John Porter, Patricia Evans, Janet L. Kwiatkowski, Ellis J. Neufeld, Thomas Coates, Patricia J. Giardina, Robert W. Grady, Elliott Vichinsky, Nancy F. Olivieri, Felicia Trachtenberg, Daniele Alberti, Jaymes Holland, Ellen Fung, Bruce Ames, Annie Lui, Paul Harmatz
Journal: Blood (2007)
Alternative Donor Transplantation Using Intensified Conditioning, T-Cell-Replete HLA-Haploidentical Grafts and Post-Transplantation Cyclophosphamide in the Treatment of High-Risk and Advanced ALL: Feasibility and Outcome
Authors: Anna-Katharina Zoellner, Dusan Prevalsek, Thomas Köhnke, Susanne Fritsch, Christoph Schulz, Max Hubmann, Stephanie Lippl, Stephan Kruger, Sarah Häbe, Sophie Berking, Alessia Fraccaroli, Georg Ledderose, Hans-Joachim Stemmler, Karsten Spiekermann, Wolfgang Hiddemann, Gesine Bug, Andreas Hausmann, Christoph Schmid, Michael H. Albert, Johanna Tischer
Journal: Blood (2016)
Improved Survival with Ursodeoxycholic Acid Prophylaxis in Allogeneic Stem Cell Transplantation: Long-Term Follow-up of a Randomized Study of the Nordic Bone Marrow Transplantation Group
Authors: Tapani Ruutu, Eeva Juvonen, Mats Remberger, Kari Remes, Liisa Volin, Jonas Mattsson, Anne Nihtinen, Hans Hagglund, Olle Ringden
Journal: Blood (2011)
5q Deletions in MDS and MPN: The Accompanying Molecular Mutations Determine the Phenotype but TP53 Is Frequently Mutated in All Entities: MPN, MDS and MPN/MDS Overlap
Authors: Claudia Haferlach, Manja Meggendorfer, Susanne Schnittger, Melanie Zenger, Wolfgang Kern, Torsten Haferlach
Journal: Blood (2014)
HY Disparity Influences Outcomes of HLA-Matched Unrelated Allo-HSCT.
Authors: Miroslaw Markiewicz, Urszula Siekiera, Monika Dzierzak Mietla, Agnieszka Karolczyk, Tomasz Kruzel, Grzegorz Helbig, Slawomira Kyrcz Krzemien
Journal: Blood (2009)
Circulating Periostin Is Elevated in Patients with Multiple Myeloma and Correlates with Advanced Disease Features and High Bone Resorption,
Authors: Evangelos Terpos, Dimitrios Christoulas, Maria Gkotzamanidou, Evangelos Eleutherakis-Papaiakovou, Athanasios Papatheodorou, Anastasia Pouli, Efstathios Kastritis, Meletios Athanasios Dimopoulos
Journal: Blood (2011)
TYK2-STAT1 Pathway Positively Regulates BCL2 Gene Expression in T-Cell Acute Lymphoblastic Leukemia
Authors: Takaomi Sanda, Jeffrey W Tyner, Alejandro Gutierrez, Vu N Ngo, Jason M Glover, Bill H Chang, Arla J Yost, Andrew P Weng, Wenxue Ma, Jessica Tatarek, Angela G. Fleischman, Yebin Ahn, Yandan Yang, Wenjun Zhou, Donna S. Neuberg, Richard Moriggl, Mathias Müller, Michelle Kelliher, Catriona Jamieson, Nathanael S Gray, Louis M. Staudt, Brian J. Druker, Thomas Look
Journal: Blood (2012)
Real-World Effectiveness and Safety of Nivolumab in NSCLC pts in Japan: A Multicenter-Retrospective Observational Study
Authors: Haruhiro Saito, Ryo Morita, Kyoichi Okishio, Junichi Shimizu, Hiroshi Sakai, Young Hak Kim, Osamu Hataji, Makiko Yomota, Makoto Nishio, Keisuke Aoe, Osamu Kanai, Toru Kumagai, Kayoko Kibata, Hiroaki Tsukamoto, Satoshi Oizumi, Keisuke Tomii, Hiroshi Tanaka, Keiko Mizuno, Hirotoshi Hoshiyama, Kenya Ochi, Yuichiro Ohe
Journal: Annals of Oncology (2019)
Daratumumab, a Novel Potent Human Anti-CD38 Monoclonal Antibody, Induces Significant Killing of Human Multiple Myeloma Cells: Therapeutic Implication.
Authors: Yu-Tzu Tai, Michel de Weers, Xian-Feng Li, Weihua Song, Sabikun Nahar, Joost M Bakker, Tom Vink, Daniëlle Jacobs, Lukas Oomen, Wim K Bleeker, Nikhil C. Munshi, Jan G. J. van de Winkel, Paul W. H. I. Parren, Paul Richardson, Kenneth C. Anderson
Journal: Blood (2009)
A pilot survey on the outpatient chemotherapy unit of national university hospitals in Japan for early palliative care
Authors: Hidenori Takahashi, Yuji Satomi, Takeshi Suzuki, Shogo Uneoka, Takeo Ishii, Aritomo Nanba, Natsumi Iguchi, Katsuya Takemura, Nobuhisa Nakajima, Masato Masuda, Akira Arasaki
Journal: Annals of Oncology (2019)
Whole Transcriptome Sequencing (RNAseq) As a Comprehensive, Cost-Efficient Diagnostic Tool for Acute Myeloid Leukemia
Authors: Marieke Griffioen, Wibowo Arindrarto, Daniel Borràs, Saskia A.M.E. van Diessen, Edith D. van der Meijden, M. Willy Honders, Mariam Alloul, Inge Jedema, Wilma G.M. Kroes, Peter J.M. Valk, Bart Janssen, Cornelis A.M. van Bergen, Szymon M. Kiełbasa, Jeroen F.J. Laros, Peter A.C. 't Hoen, Hendrik Veelken
Journal: Blood (2016)
A Phase II Multicenter Study of Lenalidomide in Relapsed or Refractory Classical Hodgkin Lymphoma.
Authors: Todd A Fehniger, Sarah Larson, Kathryn Trinkaus, Marilyn J Siegel, Amanda F Cashen, Kristie A Blum, Timothy S. Fenske, David D Hurd, Andre Goy, John F. DiPersio, Nancy L Bartlett
Journal: Blood (2009)
5-Azacitidine Therapy in Patients with Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia and Acute Myeloid Leukemia: a Single Institution Experience
Authors: Alessandra Freyrie, Gianluigi Reda, Daniele Vincenti, Mariarita Sciumé, Francesca Binda, Francesca Guidotti, Agostino Cortelezzi
Journal: Blood (2012)
Synergistic Transactivation of the Sis-Inducible Element by STAT4/STAT3 Heterodimer in Cytokine Signal Cascade.
Authors: Takehiro Higashi, Junichi Tsukada, Takamitsu Mizobe, Fumihiko Mouri, Ai Matsuura, Yasuhiro Minami, Yasuhiro Yoshida, Yoshiya Tanaka
Journal: Blood (2006)
A Multi-Institutional Retrospective Analysis of Tyrosine Kinase Inhibitor (TKI) Clinical and Preclinical Efficacy According to BCR-ABL Mutation Status in CP-CML Patients
Authors: Victor M. Rivera, Susan Branford, Franck E. Nicolini, Justin R. Pritchard, Joseph M. Gozgit, Wolfgang Kern, Dragana Milojkovic, Simone Claudiani, Martin C. Muller, Srinivas K Tantravahi, Michael W. Deininger, Michael Heinrich, Simona Soverini, Michele Baccarani, Jerald P. Radich, Elias Jabbour, Jorge E. Cortes, Gabriel Etienne, Torsten Haferlach
Journal: Blood (2015)
PTEN Loss Mediates Clinical Cross-Resistance to CDK4/6 and PI3Kα Inhibitors in Breast Cancer
Authors: Carlotta Costa, Ye Wang, Amy Ly, Yasuyuki Hosono, Ellen Murchie, Charlotte S. Walmsley, Tiffany Huynh, Christopher Healy, Rachel Peterson, Shogo Yanase, Charles T. Jakubik, Laura E. Henderson, Leah J. Damon, Daria Timonina, Ioannis Sanidas, Christopher J. Pinto, Mari Mino-Kenudson, James R. Stone, Nicholas J. Dyson, Leif W. Ellisen, Aditya Bardia, Hiromichi Ebi, Cyril H. Benes, Jeffrey A. Engelman, Dejan Juric
Journal: Cancer Discovery (2019)

Abstract The combination of CDK4/6 inhibitors with antiestrogen therapies significantly improves clinical outcomes in ER-positive advanced breast cancer. To identify mechanisms of acquired resistance, we analyzed serial biopsies and rapid autopsies from patients treated with the combination of the CDK4/6 inhibitor ribociclib with letrozole. This study revealed that some resistant tumors acquired RB loss, whereas other tumors lost PTEN expression at the time of progression. In breast cancer cells, ablation of PTEN, through increased AKT activation, was sufficient to promote resistance to CDK4/6 inhibition in vitro and in vivo. Mechanistically, PTEN loss resulted in exclusion of p27 from the nucleus, leading to increased activation of both CDK4 and CDK2. Because PTEN loss also causes resistance to PI3Kα inhibitors, currently approved in the post-CDK4/6 setting, these findings provide critical insight into how this single genetic event may cause clinical cross-resistance to multiple targeted therapies in the same patient, with implications for optimal treatment-sequencing strategies. Significance: Our analysis of serial biopsies uncovered RB and PTEN loss as mechanisms of acquired resistance to CDK4/6 inhibitors, utilized as first-line treatment for ER-positive advanced breast cancer. Importantly, these findings have near-term clinical relevance because PTEN loss also limits the efficacy of PI3Kα inhibitors currently approved in the post-CDK4/6 setting. This article is highlighted in the In This Issue feature, p. 1
Predictive Factors of Stable Deep Molecular Response in Chronic Myeloid Leukemia Patients Treated with Imatinib Standard Dose: A Study from the Gruppo Triveneto LMC
Authors: Massimiliano Bonifacio, Luigi Scaffidi, Gianni Binotto, Federico De Marchi, Elena Maino, Elisabetta Calistri, Angela Bonalumi, Luca Frison, Luciana Marin, Marta Medeot, Giovanna De Matteis, Renato Fanin, Gianpietro Semenzato, Achille Ambrosetti, Mario Tiribelli
Journal: Blood (2015)
Personalizing cancer treatment using gene activity scores with the NIH Medical Genetics Summaries.
Authors: Adriana J. Malheiro, Laura Charlotte Dean, Brandi L. Kattman
Journal: Journal of Clinical Oncology (2019)

e22000 Background: Oncology professionals need to access a wide range of genetic tests, including tests for cancer biomarkers, predisposition to hereditary cancers, and pharmacogenetic tests. While pharmacogenetic testing is fundamental to personalized medicine, the adoption of testing has been slow, partly due to a lack of readily accessible information about new developments, such as gene activity scores. Methods: Medical Genetics Summaries (MGS) was created to bridge the translation gap between genetic test results and personalized treatment plans. MGS is a free, regularly updated, peer-reviewed pharmacogenetics resource. The complete set of summaries can be browsed online or saved as PDF (www.ncbi.nlm.nih.gov/books/n/gtrbook). Excerpts of the summaries can be found via PubMed (www.pubmed.gov) and MedGen (www.ncbi.nlm.nih.gov/medgen). Results: Of the 45 drug-gene interactions included so far in MGS, 10 are commonly used cancer drugs. These include capecitabine (Xeloda) and fluorouracil (Adrucil), which are both fluoropyrimidines—antimetabolite drugs used in the treatment of colon cancer and breast cancer. The DPYD gene encodes the rate-limiting enzyme for the breakdown of fluoropyrimidines. Patients with specific variations in the DPYD gene (e.g., DPYD*2A, DPYD*13) have decreased or absent enzyme activity. In these patients, the standard recommended dose of fluoropyrimidine can cause life-threatening bone marrow suppression and neurotoxicity. MGS presents the dosing recommendation for each DPYD phenotype, which are clearly defined using the recently assigned DPYD activity scores, from authoritative professional guidelines such as the National Comprehensive Cancer Network (NCCN) and the Clinical Pharmacogenetics Implementation Consortium (CPIC), in addition to the FDA. MGS also provides an overview of the drug (drug class, mechanism of action, adverse events), an introduction to the gene(s) and significant alleles, and guidance on genetic testing—along with links to the relevant tests in the NIH Genetic Testing Registry (GTR, www.ncbi.nlm.nih.gov/gtr). Conclusions: This presentation will demonstrate how NIH precision medicine resources, with a focus on MGS, can simplify the process of ordering and interpreting pharmacogenetic tests and efficiently tailor care for your patient.
Primary Failure Diffuse Large B Cell Lymphoma: Early Autologous or Donor Hematopoietic Cell Transplantation Not Effective in Patients with Ultra-High Risk Features
Authors: Luciano J. Costa, Nishitha Reddy, Kami J. Maddocks, Narendranath Epperla, Reem Karmali, Veronika Bachanova, Elvira Umyarova, Zheng Zhou, Martha Glenn, Julio C. Chavez, Francisco J. Hernandez-Ilizaliturri, Cristiana A Costa, Nasheed Mohammad Hossain, Oscar Calzada, Zeina Al-Mansour, Ana Xavier, Andrew Evans, Saurabh Chhabra, Michael V. Jaglal, Stefan Klaus Barta, Frederick Lansigan, Christopher Flowers, Timothy S. Fenske, Jonathon B. Cohen, Mehdi Hamadani
Journal: Blood (2016)
Timely Molecular Monitoring and Achievement of Major Molecular Response in Chronic Myeloid Leukemia
Authors: Adi J. Klil-Drori, Laurent Azoulay, Hui Yin, Alexa Del Corpo, Michaël Harnois, Michel-Olivier Gratton, Ines Chamakhi, Robert Delage, Luigina Mollica, Pierre Laneuville, Harold J. Olney, Lambert Busque, Sarit E. Assouline
Journal: Blood (2016)
Monitoring of FVIII Replacement Therapy with Cell-Based Monitoring Tests.
Authors: Steffen Bassus, Wolfgang Wegert, Manuela Krause, Inge Scharrer, Thomas Scholz, Carmen Escuriola-Ettinghausen, Annelie Siegemund, Wolfhart Kreuz, Lothar Engelmann, Carl M. Kirchmaier
Journal: Blood (2004)
The Re-Activation of FoxO3 Transcription Factor in Acute Myeloid Leukaemia Is Responsible for the Induction of a Quiescent Status of Leukaemic Progenitor Cells.
Authors: Daniela Cilloni, Cristina Panuzzo, Francesca Arruga, Francesca Messa, Monica Pradotto, Enrico Bracco, Alessandro Morotti, Emanuela Messa, Antonia Rotolo, Ilaria Iacobucci, Chiara Marrè, Marisa Pautasso, Giovanni Martinelli, Giuseppe Saglio
Journal: Blood (2008)
5-Azacytidine (5-AZA) Salvage Therapy for Very High Risk Acute Myeloid Leukemia (AML): Response After 3 Cycles Is the Major Determinant for Outcome.
Authors: Sameh Ayari, Patrice Chevallier, Thierry Guillaume, Eolia Brissot, Steven Le Gouill, Mohamad Mohty, Nicolas Blin, Thomas Gastinne, Philippe Moreau, Jean Luc Harousseau, Jacques Delaunay
Journal: Blood (2009)
Functional Geriatric Assessment (F-GA) in Multiple Myeloma Patients: Results from a Prospective Multicenter Study Group (DSMM) Trial and Changes from Baseline to Follow-up Assessment
Authors: Sophia Scheubeck, Sandra Maria Dold, Gabriele Ihorst, Alexander Zober, Stefan J. Müller, Christian Langer, Wolfram Pönisch, Lars-Olof Mügge, Stefan Knop, Justus Duyster, Martin Schumacher, Ralph M. Waesch, Monika Engelhardt
Journal: Blood (2016)
The Dose-Dependent Effects of Microrna-155 in Acute Myeloid Leukemia
Authors: Nisha Narayan, Leah Morenos, Belinda Phipson, Gabriella Brumatti, Stefanie Eggers, Richard Saffery, Simon Willis, Alicia Oshlack, Gregory J Goodall, Paul G Ekert
Journal: Blood (2016)
Nilotinib Combined With Multi-Agent Chemotherapy For Adult Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Final Results Of Prospective Multicenter Phase 2 Study
Authors: Dae-Young Kim, Young Don Joo, Sung-Doo Kim, Jung-Hee Lee, Je-Hwan Lee, Dong-Hwan Kim, Kihyun Kim, Chul Won Jung, Inho Kim, Sung-Soo Yoon, Seonyang Park, Jae-Sook Ahn, Deok-Hwan Yang, Je-Jung Lee, Yang Soo Kim, Yeung-Chul Mun, Hawk Kim, Joon Ho Moon, Sang Kyun Sohn, Won Sik Lee, Jong-Ho Won, Myoung Soo Hyun, Jinny Park, Jae Hoon Lee, Ho-Jin Shin, Hyeon Seok Eom, Gyeong Won Lee, Sung-Nam Lim, Young Jin Kim, Young-Uk Cho, Hyun-Sook Chi, Kyoo-Hyung Lee
Journal: Blood (2013)
Identification of Optimized Compound Combinations for the Treatment of NUP98-NSD1+ AML
Authors: Jarno Kivioja, Angeliki Thanasopoulou, Mika Kontro, Bhagwan Yadav, Muntasir Mamun Majumder, Heikki Kuusanmäki, Alun Parsons, Kimmo Porkka, Juerg Schwaller, Caroline A Heckman
Journal: Blood (2016)
Structure-Activity Relationship of Pro- and Anticoagulant Effects of Fucus Vesiculosus Fucoidan
Authors: Michael Dockal, Susanne Till, Zhenqing Zhang, Sabine Knappe, Sabrina Reutterer, Catherine Quinn, Christoph Redl, Hartmut J. Ehrlich, Friedrich Scheiflinger, Christina Szabo
Journal: Blood (2012)
The results of Japanese subgroup analyses from TAGS: a phase 3 study of FTD/TPI (TAS-102) in heavily pretreated mGC
Authors: Ayumu Hosokawa, Kohei Shitara, Kazuhiro Nishikawa, Kazumasa Fujitani, Hisashi Hosaka, Keisuke Koeda, Yoichi Makari, Kenji Amagai, Seigo Yukisawa, Takayuki Ando, David H. Ilson, Josep Tabernero, Toshihiko Doi
Journal: Annals of Oncology (2019)
Targeting CD38 Suppresses Induction and Function of T Regulatory Cells to Reverse Immunosuppression in Multiple Myeloma
Authors: Xiaoyan Feng, Chirag Acharya, Gang An, Kenneth Wen, Li Zhang, Alireza Kalbasi, Lugui Qiu, Nikhil C Munshi, Yu-Tzu Tai, Kenneth C. Anderson
Journal: Blood (2016)
A Phase I/II Study of BHQ880, a Novel Osteoblat Activating, Anti-DKK1 Human Monoclonal Antibody, in Relapsed and Refractory Multiple Myeloma (MM) Patients Treated with Zoledronic Acid (Zol) and Anti-Myeloma Therapy (MM Tx).
Authors: Swaminathan Padmanabhan, Joseph Thaddeus Beck, Kevin R. Kelly, Nikhil C. Munshi, Andy Dzik-Jurasz, Esha Gangolli, Seth Ettenberg, Kelly Miner, Sanela Bilic, Winston Whyte, Fazal Mehdi, Lu-May Chiang, Patricia Liz Rae, Andrew Spencer, Jatin Shah, Kenneth C. Anderson, Francis J. Giles, A. Keith Stewart
Journal: Blood (2009)
NIK Is Involved In the Activation of the Classical and Alternative NF-κB Pathways In Diffuse Large B Cell Lymphoma
Authors: Lina Odqvist, Margarita Sánchez-Beato, Santiago Montes-Moreno, Ken H Young, Francesco Acquadro, Juan Cigudosa, Jose A Martinez-Climent, Anabel Sáez, Lydia Sánchez, Miguel A. Piris
Journal: Blood (2010)
Patients' Perspectives on the Definition of Cure in Chronic Myeloid Leukemia: A US Based Survey
Authors: Gemlyn George, Ehab L. Atallah, Michael J. Mauro, Stuart L. Goldberg, Arielle Baim, Jessica Guhl, Alexander Hinman, Jorge E. Cortes, Michael W. Deininger, Brian J. Druker, Vamsi K Kota, Richard A. Larson, Jeffrey H. Lipton, Joseph O. Moore, Vivian G. Oehler, Javier Pinilla Ibarz, Jerald Radich, Ellen K. Ritchie, Charles A. Schiffer, Neil P. Shah, Richard T. Silver, Kendra L. Sweet, James E. Thompson, Martha Wadleigh, Kathryn E Flynn
Journal: Blood (2018)